CD69 and myeloid sarcoma: To address this goal, we evaluated the proportion and activation status (measured by CD69 expression) of circulating NK subsets (regCD56bright and cytCD56dim) and CD3+CD56+CD8+ cells in both men and women from healthy subjects, MS patients, and pregnant women.